Related by context. All words. (Click for frequent words.) 76 symptomatic VTE 74 oxycodone CR 73 moderate renal impairment 73 #.#/#.# mmHg [001] 72 PASI scores 72 recurrent DVT 72 Thal Dex 72 lopinavir r arm 72 hyperphenylalaninemia HPA due 72 CIMZIA ™ 72 prednisone prednisolone plus 72 lumbar spine BMD 71 prospectively stratified 71 ACTEMRA TM 71 everolimus eluting stents 71 receiving XGEVA 71 PLX STROKE targeting 71 Erythropoietic therapies may 71 NATRECOR ® 71 #mg BID [001] 71 urinary N telopeptide 71 binary restenosis 71 ATACAND 71 tapentadol ER 71 XIENCE V PROMUS Stent 71 colorectal adenoma 71 haematologic 71 subtrochanteric 71 thromboembolic complications 71 EDEMA3 trial 71 β blockers 71 Non inferiority 70 recurrent venous thromboembolism 70 deep venous thromboses 70 recurrent glioblastoma multiforme 70 rosuvastatin #mg 70 8mg/kg 70 intravascular hemolysis 70 adenoma recurrence 70 glycated hemoglobin HbA1c 70 secondary efficacy endpoint 70 vertebral fracture 70 CIMZIA TM certolizumab pegol 70 elevated transaminases 70 desvenlafaxine succinate 70 arterial thromboembolic events 70 Subgroup analysis 70 hip BMD 70 serum aminotransferase levels 70 NMIBC 70 Primary endpoints 70 achieved statistical significance 70 glycated hemoglobin levels 70 mL/min/#.# m 2 70 serum phosphorous 70 QTcF 70 intima media thickness 70 CR nPR 70 nonvertebral fracture 70 headache nasopharyngitis 70 reduce serum phosphate 70 PRADAXA #mg 70 pyridostigmine 69 corticosteroid dose 69 response CCyR 69 ischemic cardiomyopathy 69 perioperative complications 69 angiographic outcomes 69 mg BID dose 69 CCyR 69 left ventricular diastolic 69 ARB telmisartan 69 keloid scarring 69 mcg QD 69 intravesical therapy 69 neurologic progression 69 TAXUS p value 69 locoregional recurrence 69 antiretroviral naïve 69 salmeterol fluticasone 69 FOLFOX6 69 paroxysmal AF 69 definite stent thrombosis 69 hypophosphatemia 69 nonvertebral fractures 69 relapsed MM 69 atrioventricular block 69 prospectively defined 69 eplerenone 69 STRIDE PD 69 LV dysfunction 69 nicardipine 69 somatostatin analog 69 aminotransferases 69 nondiabetic patients 69 biochemical relapse 69 prespecified secondary 69 aspartate aminotransferase AST 69 Tasigna prolongs 69 TAXUS Express Stent 69 intraobserver 69 severe exacerbations 69 rFVIIa 69 Hypotension 69 serum calcium levels 69 recurrent ischemia 69 postoperative mortality 69 tolvaptan 69 vitreous floaters 69 PEGINTRON TM 69 TAXUS Liberte Long 69 CIMZIA TM 69 repeat paracentesis 69 lipid lowering agents 69 XIENCE V demonstrated 69 serum urate 69 biologic DMARD 69 Postoperative complications 69 metformin monotherapy 69 achieved ACR# 69 #mg dose [002] 69 infliximab monotherapy 69 GOUT 69 baseline HbA1c 69 KRAS mutations occur 69 RoACTEMRA 69 echocardiographic parameters 69 oral rivaroxaban 69 comparator arm 69 serum phosphate 69 linaclotide treated 69 doxorubicin docetaxel 68 osteoporotic vertebral compression fractures 68 symptomatic intracranial 68 lumbar disk herniation 68 non vertebral fractures 68 moderate hepatic impairment 68 Arch Intern Med 68 ertapenem 68 endometrial thickness 68 reinfarction 68 adjunctive placebo 68 FluCAM arm 68 complete cytogenetic response 68 PSA nadir 68 perioperative mortality 68 neutropenia dehydration dyspnea 68 anagrelide 68 multivariate Cox 68 conjunctival hyperemia 68 plus dexamethasone 68 postintervention 68 postoperative chemotherapy 68 liver histology 68 BENICAR HCT 68 perioperative morbidity 68 ximelagatran 68 NPH insulin 68 FOLFOX4 68 Stent thrombosis 68 Am J Cardiol 68 demonstrated clinically meaningful 68 angiographic restenosis 68 aldosterone antagonist 68 atorvastatin #mg 68 postoperative complication 68 HBeAg seroconversion 68 IIIa inhibitor 68 postoperative morbidity 68 venous thromboembolic disease 68 Hb A1C 68 tumor necrosis 68 tolterodine ER 68 antiarrhythmic drug 68 Mg Uk 68 ischemia driven 68 chemoradiation therapy 68 oral levofloxacin 68 #.#mg/dL 68 PREZISTA r arm 68 achieved CCyR 68 transaminase elevations 68 intravenous bisphosphonates 68 postoperative pulmonary 68 microbiological eradication 68 gadolinium enhancing lesions 68 Index CDAI 68 anthracycline taxane 68 cerebrovascular events 68 mcg BID 68 clinically meaningful reductions 68 ADCS CGIC 68 CTEPH 68 myocardial infarction ventricular fibrillation 68 periprocedural 68 EDARBI 68 APTIVUS r 68 ARCALYST ® 68 annualized relapse 68 intact parathyroid hormone 68 postoperative AF 68 carotid artery intima media 68 REYATAZ r arm 68 Infusion Reactions Severe 68 pyrexia mucositis sepsis febrile 68 phase IIb study 68 paricalcitol 68 nonoperative treatment 68 hematologic toxicity 68 Primary Hypercholesterolemia 68 RAPAFLO R 68 carotid intima media 68 cardiovascular hospitalizations 68 R# #mg BID 68 mineral density BMD 68 calcaneal fractures 67 unresectable HCC 67 zonisamide SR 67 Flu Cy 67 nadroparin 67 recurrent VTE 67 Pharmacokinetic parameters 67 oral diclofenac 67 pCR 67 carotid stenosis 67 TLUS 67 Postoperatively 67 nonrandomized 67 oral antidiabetic medication 67 catheter occlusion 67 myocardial reperfusion 67 DAS# CRP 67 embolic stroke 67 CI -#.# 67 extrapyramidal symptoms 67 pharmacokinetic equivalence 67 chondral 67 SVR# 67 intraoperative complications 67 ruboxistaurin 67 pain palliation 67 Ceplene/IL-2 67 percutaneous vertebroplasty 67 CP CPPS 67 CTAP# Capsules 67 CYT# potent vascular disrupting 67 #Gy 67 FUSILEV enhances 67 MAGE A3 ASCI 67 VIIBRYD 67 EXJADE 67 urate lowering therapy 67 plus methotrexate 67 artery stenosis 67 graft occlusion 67 systemic embolism 67 interferon ribavirin 67 LymphoStat B belimumab 67 β blocker 67 ibandronate 67 colesevelam HCl 67 calculated creatinine clearance 67 INCB# [003] 67 evaluating tivozanib 67 nasopharyngitis headache 67 hemodynamically significant 67 TO AVOID PREGNANCY WHILE 67 abacavir lamivudine 67 systemic corticosteroid 67 candesartan cilexetil 67 PCWP 67 sitaxsentan 67 lumbar spine bone 67 Operative mortality 67 neutrophil counts 67 VELCADE melphalan 67 weekly subcutaneous injections 67 NNT = 67 ulnar styloid 67 stage IIIb IV 67 Febrile neutropenia 67 tipranavir r 67 activated partial thromboplastin 67 nonfasting triglyceride levels 67 venlafaxine XR 67 hemoglobin A1c levels 67 revascularizations 67 beta blocker therapy 67 pathologic fracture 67 dopaminergic therapy 67 4mg/kg 67 proximal DVT 67 acetabular dysplasia 67 CYP#A# CYP#D# 67 atherogenic dyslipidemia 67 PSADT 67 cartilage lesions 67 Drug eluting stent 67 ONGLYZA saxagliptin 67 Cardiopulmonary bypass 67 microbiologically evaluable 67 TWYNSTA 67 interobserver reliability 67 certolizumab 67 zoledronate 67 azilsartan medoxomil 67 receiving PEGINTRON 67 solifenacin 67 weekly CSBMs 67 non valvular atrial 67 reactogenicity 67 infarct size 67 Ishak fibrosis score 67 IOP lowering 67 baseline serum creatinine 67 tibial shaft 67 % CI #.#-#.# [003] 67 nonfatal MI 67 BYSTOLIC 67 unstable angina pectoris 67 CRESTOR #mg 67 aspartate aminotransferase 67 MS relapses 67 invasive aspergillosis 67 androgen suppression 67 CC genotype 67 aspirin clopidogrel 67 alteplase 67 generalized edema 67 â ‰ ¥ 67 systemic hypotension 67 hemorrhagic complications 66 zolmitriptan 66 paclitaxel eluting stents 66 atheroma volume 66 radiographic outcomes 66 naïve HCV 66 unfractionated heparin UFH 66 fatigue abdominal pain 66 tirofiban 66 RECORD1 66 carotid IMT 66 budesonide pMDI 66 Xelox 66 femoral neck fracture 66 MERLIN TIMI 66 bone marrow reticulin deposition 66 Kaplan Meier analysis 66 MGd 66 idraparinux 66 nadolol 66 ExTRACT TIMI 66 statistically significant p = 66 lactate dehydrogenase LDH 66 Crohn Disease Activity 66 Secondary endpoints included 66 5-FU/LV 66 glycosylated hemoglobin levels 66 TNF antagonist 66 J Am Coll 66 sUA 66 QTc prolongation 66 HCV RESPOND 2 66 PREZISTA r 66 abnormal p# biomarker 66 ventricular remodeling 66 Secondary endpoints include 66 apolipoprotein B 66 irbesartan 66 pegylated interferon peg IFN 66 ACAPODENE 66 attain statistical significance 66 ARCOXIA 66 efficacy endpoint 66 atherothrombotic events 66 Zemplar Capsules 66 Refractory Hodgkin Lymphoma 66 urine albumin 66 mcg kg REBETOL 66 mitoxantrone plus 66 metastatic colorectal carcinoma 66 carotid artery blockage 66 cardiovascular hospitalization 66 incidence ≥ 66 induce orthostatic hypotension 66 FOLPI 66 placebo dexamethasone 66 clevidipine 66 fluticasone salmeterol 66 carotid artery stenting CAS 66 receiving golimumab 66 evaluable subjects 66 NIHSS score 66 macroalbuminuria 66 unresectable tumors 66 clodronate 66 plain radiographs 66 pericardial effusion 66 statin monotherapy 66 surgically induced 66 NYHA functional class 66 Doxil ® 66 REMINYL ® 66 detrusor overactivity 66 vidofludimus 66 ribavirin RBV 66 novel VDA molecule 66 ULORIC 66 BCG refractory carcinoma 66 WOMAC pain 66 biphasic insulin aspart 66 nodular partial response 66 acute mania 66 androgen deprivation 66 TEAEs 66 serum uric acid sUA 66 glycosylated hemoglobin HbA1c 66 virologic response 66 anemia hemoglobin 66 ZOLINZA 66 composite endpoint 66 macrovascular 66 mixed hyperlipidemia 66 Known hypersensitivity 66 TAXUS Liberté stent 66 FOSRENOL ® 66 metastatic malignant 66 NYHA Class II 66 Bankart lesion 66 #mg/day [002] 66 Key secondary endpoints 66 basal bolus regimen 66 posaconazole 66 INVEGA ® 66 FOLFIRI 66 Ribavirin causes 66 mild renal insufficiency 66 AST ALT 66 CYPHER Stent 66 gout flares 66 retinal vein occlusion induced 66 periprocedural MI 66 Thalomid ® 66 proliferative retinopathy 66 overt hepatic encephalopathy HE 66 genotypic resistance 66 -#.# log# 66 antithrombotic therapy 66 atherosclerotic renal artery stenosis 66 lymphopenia 66 EGFR TKI 66 Cypher Stent 66 QTc intervals 66 left ventricular systolic 66 Subarachnoid hemorrhage 66 Vascugel ® 66 elevated IOP 66 Hazard Ratio HR 66 anastomotic leak 66 HMG CoA reductase inhibitors 66 severe renal impairment 66 multivariable adjusted 66 rimonabant #mg/day 66 cisplatin vinorelbine 66 ALA PDT 66 NATRECOR R 66 rebleeding 66 LV ejection fraction 66 dalteparin 66 albumin excretion rate 66 cytopenias 66 esophagogastric 66 symptomatic pulmonary embolism 66 ug dose 66 dosing cohort 66 Patency 66 FDA defined valvulopathy 66 TNF Tumor Necrosis Factor 66 sirolimus eluting stents 66 Mg Usa 66 ACE inhibitor ramipril 66 administering XIFAXAN 66 AA Amyloidosis 66 HbA1C levels 66 symptomatic intracranial hemorrhage 66 CIMZIA R 66 -#.# mg dL [002] 66 angina myocardial infarction 66 Helicobacter pylori eradication 66 CINQUIL 66 sotalol 66 postprocedure 66 asymptomatic carotid stenosis 66 hematological parameters 66 benazepril 66 SIMPADICO 66 % CI #.#-#.# [005] 66 Sustained virologic response 66 ABC/3TC 66 Eur J Endocrinol 66 thrombotic complications 66 Percutaneous vertebroplasty 66 HOMA IR 66 confidence interval #.#-#.# 66 Tumor Response 66 salmeterol HFA MDI 66 rheumatoid arthritis osteoarthritis ankylosing 66 fallopian tube cancers 66 prolonged QT interval 66 intracranial atherosclerosis 66 titrated glipizide 66 euthymic patients 66 Zometa hazard 66 CI #.#-#.# [001] 66 rimonabant #mg 66 pravastatin therapy 65 Retreatment 65 intravitreal injections 65 STRATEGY FOR AN OPEN 65 irinotecan cisplatin 65 arteriography 65 neutropenia thrombocytopenia 65 dose Iluvien 65 variant angina 65 statistical significance p 65 dyslipidaemia 65 Hormone Refractory Prostate Cancer 65 MACCE 65 systolic dysfunction 65 ipsilateral stroke 65 serum triglycerides 65 spirometric 65 Carotid artery 65 coronary revascularization procedures 65 transfusion syndrome 65 hypercholesterolaemia 65 RE LY ® 65 metastatic GIST 65 HBeAg negative 65 riociguat 65 brand ciclesonide HFA 65 metastatic bone 65 -#.# mg dL [001] 65 postoperative infections 65 patients undergoing CABG 65 Scale EDSS 65 bronchial hyperresponsiveness 65 hsCRP levels 65 receiving INTRON 65 alanine aminotransferase ALT 65 zoledronic acid Reclast 65 SPRYCEL ® 65 HbA 1c levels 65 pulmonary exacerbations 65 chronic periodontitis 65 resynchronization therapy 65 #q# deletion syndrome 65 FOLFOX6 chemotherapy regimen 65 colorectal liver metastases 65 recurrent malignant glioma 65 Lupuzor ™ 65 HIV HCV coinfected 65 posttreatment 65 Inventory BPI 65 tamoxifen Nolvadex ® 65 FOLFIRI alone 65 T2 lesions 65 radiotherapy RT 65 Ophena TM 65 Ann Oncol 65 cardiac perfusion 65 PRADAXA 65 prostate carcinoma 65 Secondary efficacy endpoints 65 ritonavir boosted 65 VADT 65 subsyndromal 65 avosentan 65 glycoprotein IIb IIIa inhibitor 65 relapsed MCL 65 fasting plasma glucose FPG 65 advanced adenoma 65 Hypertrophy 65 tibiofemoral 65 CYP#A# substrate 65 clinically meaningful improvement 65 interobserver 65 foveal thickness 65 Intravitreal 65 pulmonary artery banding 65 radiochemotherapy 65 dysuria 65 Nesiritide 65 reoperations 65 angiotensin analog 65 serum urate levels 65 MADRS score 65 hypercalcaemia 65 #mg QD [001] 65 postoperative infection 65 serum creatinine levels 65 placebo controlled clinical 65 HuMax EGFr 65 either acutely decompensated 65 oral FTY# 65 chronic thromboembolic pulmonary 65 prospective multicentre 65 Perforomist Inhalation Solution 65 HBeAg negative patients 65 nephrotoxicity 65 cinacalcet 65 elevated triglyceride levels 65 HbA 1c 65 octreotide LAR 65 IV bisphosphonates 65 eculizumab therapy 65 platelet inhibition 65 ß blockers 65 cytogenetic response 65 Hematologic 65 CK # plasma concentrations 65 chlorambucil 65 Virologic 65 MoxDuo TM IR 65 thromboembolism 65 leiomyomas 65 myocardial infarctions 65 hepatorenal syndrome 65 methotrexate monotherapy 65 anthracycline containing 65 CIN2 + 65 intracranial hemorrhage ICH 65 histologic subtype 65 x ULN 65 subcutaneous enoxaparin 65 post thrombotic syndrome 65 nonvertebral 65 serum lipid levels 65 myelodysplastic myeloproliferative diseases 65 malignancy HCM 65 alfa 2a 65 teriflunomide 65 HER2 expression 65 ventricular tachyarrhythmia 65 Randomized Double blind 65 pegylated liposomal doxorubicin 65 Oral Fingolimod 65 peginterferon alfa 65 preserved ejection fraction 65 bezafibrate 65 dapagliflozin plus 65 headache abdominal pain 65 parathyroid carcinoma 65 Meets Primary Endpoint 65 external genital lesions 65 cerebral vasospasm 65 hyperalgesia 65 anaphylactic reactions bronchospasm 65 coronary stenosis 65 abdominal distention 65 lenalidomide Revlimid R 65 radiographic progression 65 affective psychosis 65 BRIM2 65 glomerular filtration 65 metformin accumulation 65 SGPT 65 venous thromboembolisms 65 hemodynamically unstable 65 knee osteoarthritis OA 65 neutropenic sepsis 65 Secondary endpoints 65 PAOD 65 ACR# responses 65 worsening thrombocytopenia 65 Peginterferon 65 receiving VICTRELIS 65 Clinically significant 65 baseline FEV 65 protein excretion 65 renal toxicity 65 % Confidence Interval 65 EUFLEXXA R 65 histologically confirmed 65 dose pravastatin 65 prospective multicenter study 65 autonomic dysfunction 65 nonhematologic adverse reactions 65 J Am Soc 65 thyrotropin levels 65 N Engl J 65 neurocognitive deficits 65 serum estradiol 65 Raptiva r 65 plus prednisone prednisolone 65 gadolinium enhanced 65 antiplatelet medications 65 DLTs 65 ribavirin USP 65 carotid endarterectomy CEA 65 pegylated IFN 65 ecchymosis 65 phonophobia 65 oxycodone IR 65 metabolic parameters 65 ribavirin therapy 65 plasma triglycerides 65 receiving VELCADE 65 Adjuvant chemotherapy 65 salivary flow 65 papillary renal cell carcinoma 65 thrombotic events 65 HBV infections 65 mild hepatic impairment 65 baseline LDH 65 Nephrol Dial Transplant 65 See CLINICAL PHARMACOLOGY 65 laboratory abnormalities 65 CK # administered 65 pegaptanib 65 liver decompensation 65 clomipramine 65 fluvastatin 65 intracranial stenosis 65 postoperative bleeding 65 fractional shortening 65 primidone 65 RLAI 65 PCI ExTRACT TIMI 65 corrected QT interval 65 underwent resection 65 hemoglobin A1c HbA1c 65 ancrod 65 antibody titer 65 NSTEMI 65 schizophrenia CIAS 65 upper gastrointestinal bleeding 65 GnRH agonist 65 variceal 65 recurrent metastatic 65 Pegylated Liposomal Doxorubicin 65 lanthanum carbonate 65 virological response 65 pneumonectomy 65 arterial thrombosis 65 decompensated heart failure 65 ziconotide 65 HIV coinfected 65 Radical prostatectomy 65 Naive Patients 65 plus MTX 65 elevated ALT 65 clazosentan 65 perioperatively 65 alfuzosin 65 PegIFN RBV 65 antiplatelet drugs 65 lipid lowering therapies 65 refractory chronic lymphocytic 65 reintubation 65 XIENCE V vs. 65 Skin sterol 65 virologic failure 65 heFH 65 statistically significant efficacy 65 hypercalciuria 65 telaprevir dosed 65 non splenectomized 65 drug eluting stent implantation 65 pretest probability 65 noninferior 64 thromboembolic events 64 fondaparinux sodium 64 #mmHg [001] 64 vaginal hysterectomy 64 complement inhibitor eculizumab 64 Montgomery Asberg Depression 64 decompensated liver disease 64 Unstable Angina 64 metabolic alkalosis 64 Cimzia TM 64 aromatase inhibitor therapy 64 bupropion SR 64 nonischemic 64 aplastic anemia AA 64 doxorubicin cyclophosphamide 64 F FDG PET 64 neutropaenia 64 cEVR 64 xanthine oxidase inhibitor 64 confirmed CCyR 64 left ventricular dysfunction 64 platelet reactivity 64 RAPAFLO TM 64 intensive lipid lowering 64 choroidal neovascularization CNV 64 Thrombotic thromboembolic complications 64 valsartan amlodipine 64 gemcitabine Gemzar 64 warfarin sodium 64 oxcarbazepine 64 insulin detemir 64 occlusion CRVO 64 leukopenia 64 thromboembolic disease 64 dual endothelin receptor antagonist 64 advanced adenomas 64 Y BOCS 64 Lactic acidosis 64 QTc 64 serum clusterin levels 64 Peg IFN 64 FFNS 64 drotrecogin alfa activated 64 N telopeptide 64 neutropenia febrile neutropenia 64 fragility fracture 64 endometrial hyperplasia 64 thoracoscopic lobectomy 64 serum triglyceride levels 64 opioid naïve 64 NNRTI resistance 64 alanine aminotransferase 64 VaD 64 decompressive surgery 64 hypomagnesemia 64 hypoperfusion 64 choroidal neovascularization 64 DOXIL 64 thrombocytopenic 64 paresthesias 64 anginal pain 64 Score TOS 64 chronic idiopathic thrombocytopenic purpura 64 landmark ATHENA 64 dose proportionality 64 Ejection Fraction 64 PEGylated Fab fragment 64 hypoglycemic events 64 CR CRu 64 noninferiority 64 -#.# log# copies mL 64 symptomatic aortic stenosis 64 meniscectomy 64 cardiac dysfunction 64 natriuresis 64 mm Stent 64 pentoxifylline 64 smoldering multiple myeloma 64 kidney urologic 64 tonsillar hypertrophy 64 aneurysmal subarachnoid hemorrhage 64 eosinophilic asthma 64 revascularization procedures 64 thromboprophylaxis 64 serum uric acid 64 achieve sustained virologic 64 death reinfarction 64 % AST SGOT 64 plus prednisone 64 elevated serum creatinine 64 Heterozygous Familial Hypercholesterolemia 64 functional mitral regurgitation 64 imatinib therapy 64 prospectively evaluated 64 acutely decompensated congestive heart 64 Budesonide foam crofelemer 64 spontaneous bacterial peritonitis 64 tenofovir emtricitabine 64 Carotid Revascularization Endarterectomy vs. 64 diarrhea abdominal 64 pulmonary capillary wedge 64 heparin induced thrombocytopenia 64 NIHSS 64 undetectable HBV DNA 64 T2 lesion volume 64 triiodothyronine 64 mesalamine granules 64 creatinine clearance 64 liver transaminases 64 adalimumab Humira 64 thetreatment 64 peripheral sensory neuropathy 64 primary hypercholesterolemia 64 thromboembolic 64 systemic immunosuppressive drugs 64 Folfox 64 plasma creatinine 64 sustained virological response 64 mITT population 64 Severity MSCS score 64 mineral density 64 adjuvant systemic 64 oral Hycamtin 64 hypokalemia 64 neurologic deficits 64 vertebral fractures 64 mm Hg diastolic 64 symptomatic carotid stenosis 64 adjuvant radiotherapy 64 adrenocortical cancer 64 psychiatric comorbidity 64 reflux esophagitis 64 bortezomib refractory 64 dyspareunia 64 concomitant antibiotics 64 OAB symptoms 64 confidence intervals CIs 64 events MACE 64 sumatriptan naproxen sodium 64 symptomatic hyponatremia 64 amoxicillin clavulanate 64 plus OBT 64 micafungin 64 mg Proellex 64 ezetimibe simvastatin 64 diastolic blood pressures 64 metachronous 64 Elitek 64 recurrent genital herpes 64 trimethoprim sulfamethoxazole 64 adjunctive ABILIFY 64 proctitis 64 K ras mutations 64 HCV SPRINT 64 plasma kallikrein inhibitor 64 opioid analgesia 64 Fasting blood glucose 64 neovascular 64 creatine kinase MB 64 bovine thrombin 64 events SAEs 64 hormone receptor negative 64 GORE TAG Device 64 Relapsing Remitting Multiple Sclerosis 64 relapsing remitting MS RRMS 64 ARIXTRA 64 VTE prophylaxis 64 dermatologic reactions 64 inhibit platelet function 64 Combination therapy 64 LAGB 64 mucosal inflammation 64 sustained ventricular tachycardia 64 analgesic efficacy 64 dizziness nausea diarrhea 64 ventricular dysfunction 64 TMC# r 64 hypertrichosis occurred 64 leucopenia 64 PEGylated anti 64 GLIADEL Wafer 64 diameter stenosis 64 dacarbazine DTIC 64 eosinophil count 64 subtalar 64 macular edema secondary 64 APTIVUS ritonavir 64 fluoxetine paroxetine 64 timepoint 64 sirolimus eluting 64 Serious adverse reactions 64 dexrazoxane 64 INVEGA ™ 64 nonsignificant difference 64 AGILECT R 64 LEXIVA r 64 Intravitreal injections 64 Hepatotoxicity 64 resistant hormone refractory 64 STELARA ® 64 opioid induced bowel dysfunction 64 sargramostim 64 aMCI precursor 64 GORE VIABAHN Endoprosthesis 64 intra articular injection 64 cilostazol 64 saline placebo 64 overt nephropathy 64 prednisone prednisolone 64 Acute Ischemic Stroke 64 clinicopathological features 64 Solid Tumors criteria 64 included exfoliative dermatitis 64 humanized interleukin 6 64 MCyR 64 de novo kidney transplant 64 steroid dexamethasone 64 By JENNIFER LEARN 64 intravenous cyclophosphamide 64 % CI #.#-#.# [004] 64 mg ustekinumab 64 renal flares 64 microvascular complications 64 HER2 overexpression 64 edifoligide 64 patients coinfected 64 ejection fractions 64 pharmacodynamic parameters